Company Encyclopedia
View More
name
EAST-ASIA PHARMACEUTICAL
605177.SH
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company provides products in the fields of cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms.
3.184 T
605177.SHMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking217/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-11.39%D
    • Profit Margin-26.24%E
    • Gross Margin34.61%C
  • Growth ScoreE
    • Revenue YoY-36.76%E
    • Net Profit YoY-369.91%E
    • Total Assets YoY-3.73%D
    • Net Assets YoY-10.25%D
  • Cash ScoreE
    • Cash Flow Margin-381.03%D
    • OCF YoY-36.76%E
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreC
    • Gearing Ratio46.46%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    EAST-ASIA PHARMACEUTICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 72.41 million yuan

    According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL disclosed its third-quarter report for 2025. The company achieved a revenue of 596 million yuan in the first three quarters, a year-on-year decrease of 38.08%; the net profit attributable to shareholders was a loss of 72.41 million yuan; the net profit excluding non-recurring items was a loss of 81.98 million yuan; the basic earnings per share were -0.63 yuan

    Zhitong·
    SH
    605177
    -0.62%
    Zhitong·
    SH
    605177
    -0.62%

    The Shanghai Stock Exchange issued regulatory warnings to EAST-ASIA PHARMACEUTICAL and relevant responsible persons

    The Shanghai Stock Exchange issued a regulatory warning to Zhejiang East-Asia Pharmaceutical and related responsible persons due to discrepancies between the use of some raised funds and the initial public offering prospectus, failure to timely fulfill review procedures, and inaccurate information disclosure regarding the storage and actual use of raised funds. These actions violate relevant regulations

    Wallstreetcn·
    SH
    605177
    -0.62%
    Wallstreetcn·
    SH
    605177
    -0.62%

    Overview of A-share Stock Buybacks: Today, 4 Companies Disclosed Buyback Progress

    On August 25th, 4 companies announced their stock repurchase progress, among which 1 company disclosed its repurchase plan for the first time, and 3 companies have completed their repurchases. NJTC plans to repurchase no more than 400 million yuan. The completed repurchase amounts for JSST, Keli, and EAST-ASIA PHARMACEUTICAL are 9.3214 million yuan, 5.4361 million yuan, and 1.326 million yuan, respectively. So far this year, a total of 1,407 repurchase plans have been implemented, involving 1,105 companies, with 255 companies having repurchase amounts exceeding 100 million yuan. China COSCO Shipping, Tongwei Co., Ltd., and Jiuan Medical have the highest repurchase amounts, at 2.146 billion yuan, 2.008 billion yuan, and 1.680 billion yuan, respectively

    Zhitong·
    SH
    605177
    -0.62%
    SH
    601975
    0.00%
    SZ
    002609
    -0.10%
    Zhitong·
    SH
    605177
    -0.62%
    SH
    601975
    0.00%
    SZ
    002609
    -0.10%

    EAST-ASIA PHARMACEUTICAL: Subsidiary obtains CNAS laboratory accreditation certificate

    EAST-ASIA PHARMACEUTICAL's wholly-owned subsidiary Hangzhou Shanli Biomedical Technology Co., Ltd. has obtained the CNAS laboratory accreditation certificate, which is valid from May 20, 2025, to May 19, 2031. This accreditation enhances the laboratory's management and technical capabilities, improves the company's product quality and R&D capabilities, and promotes high-quality development, but has no significant impact on the company's current performance

    Zhitong·
    SH
    605177
    -0.62%
    Zhitong·
    SH
    605177
    -0.62%

    EAST-ASIA PHARMACEUTICAL: Levofloxacin Tablets Approved for Drug Registration Certificate

    EAST-ASIA PHARMACEUTICAL recently obtained the drug registration certificate for Levofloxacin Tablets approved by the National Medical Products Administration. This drug is used to treat various infections. Several domestic manufacturers have already obtained registration certificates, and the national sales are expected to be approximately 435 million yuan in 2024. This certificate will positively impact the company's future development

    Zhitong·
    SH
    605177
    -0.62%
    Zhitong·
    SH
    605177
    -0.62%